Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Joung JY, Sugimoto M, Sartor O, Liu YZ, Poehlein C, Barker L, Del Rosario PM, Armstrong AJ. Saad F, et al. Among authors: sugimoto m. Lancet Oncol. 2023 Oct;24(10):1094-1108. doi: 10.1016/S1470-2045(23)00382-0. Epub 2023 Sep 12. Lancet Oncol. 2023. PMID: 37714168 Clinical Trial.
The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi-institutional observational ZENSHIN study.
Uemura H, Oya M, Kamoto T, Sugimoto M, Shinozaki K, Morita K, Koto R, Takahashi M, Nii M, Shin E, Nonomura N. Uemura H, et al. Among authors: sugimoto m. Cancer Med. 2023 Mar;12(5):5265-5274. doi: 10.1002/cam4.5333. Epub 2022 Nov 10. Cancer Med. 2023. PMID: 36358026 Free PMC article.
Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium.
Olivier J, Li W, Nieboer D, Helleman J, Roobol M, Gnanapragasam V, Frydenberg M, Sugimoto M, Carroll P, Morgan TM, Valdagni R, Rubio-Briones J, Robert G, Stricker P, Hayen A, Schoots I, Haider M, Moore CM, Denton B, Villers A; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 Consortium. Olivier J, et al. Among authors: sugimoto m. Eur Urol Open Sci. 2022 Jan 3;35:59-67. doi: 10.1016/j.euros.2021.11.006. eCollection 2022 Jan. Eur Urol Open Sci. 2022. PMID: 35024633 Free PMC article.
Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database.
Beckmann K, Santaolalla A, Helleman J, Carroll P, Ha Chung B, Shiong Lee L, Perry A, Rubio-Briones J, Sugimoto M, Trock B, Valdagni R, Dasgupta P, Van Hemelrijck M, Elhage O; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Beckmann K, et al. Among authors: sugimoto m. Eur Urol Open Sci. 2021 Nov 1;34:47-54. doi: 10.1016/j.euros.2021.09.012. eCollection 2021 Dec. Eur Urol Open Sci. 2021. PMID: 34934967 Free PMC article.
Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium.
Tohi Y, Kato T, Fukuhara H, Kobayashi K, Ohira S, Ikeda K, Daizumoto K, Katayama S, Shimizu R, Nishimura K, Nagami T, Hayashida Y, Hirama H, Takamoto A, Dainichi T, Sugimoto M; Chu-shikoku Japan Urological Consortium. Tohi Y, et al. Among authors: sugimoto m. Int J Clin Oncol. 2022 Aug;27(8):1348-1355. doi: 10.1007/s10147-022-02183-z. Epub 2022 May 20. Int J Clin Oncol. 2022. PMID: 35596089
Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative.
Remmers S, Helleman J, Nieboer D, Trock B, Hyndman ME, Moore CM, Gnanapragasam V, Shiong Lee L, Elhage O, Klotz L, Carroll P, Pickles T, Bjartell A, Robert G, Frydenberg M, Sugimoto M, Ehdaie B, Morgan TM, Rubio-Briones J, Semjonow A, Bangma CH, Roobol MJ; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Remmers S, et al. Among authors: sugimoto m. Eur Urol Open Sci. 2022 Jun 14;41:126-133. doi: 10.1016/j.euros.2022.05.012. eCollection 2022 Jul. Eur Urol Open Sci. 2022. PMID: 35813247 Free PMC article.
Patient and Carer Experiences with Bladder Cancer: Results from a Global Survey in 45 Countries.
Makaroff LE, Filicevas A, Boldon S, Hensley P, Black PC, Chisolm S, Demkiw S, Fernández MI, Sugimoto M, Jensen BT, Witjes WPJ, Bagshaw K, Cirefice-Funk L, Knight A, Kamat AM. Makaroff LE, et al. Among authors: sugimoto m. Eur Urol. 2023 Aug;84(2):248-251. doi: 10.1016/j.eururo.2023.04.034. Epub 2023 May 24. Eur Urol. 2023. PMID: 37236857 No abstract available.
Post-resolution macrophages shape long-term tissue immunity and integrity in a mouse model of pneumococcal pneumonia.
Feehan KT, Bridgewater HE, Stenkiewicz-Witeska J, De Maeyer RPH, Ferguson J, Mack M, Brown J, Ercoli G, Mawer CM, Akbar AN, Glanville JRW, Jalali P, Bracken OV, Nicolaou A, Kendall AC, Sugimoto MA, Gilroy DW. Feehan KT, et al. Among authors: sugimoto ma. Nat Commun. 2024 May 21;15(1):4326. doi: 10.1038/s41467-024-48138-y. Nat Commun. 2024. PMID: 38773113 Free PMC article.
2,315 results